Peer Exchange

A panel of experts provide an overview of the burden of common health concerns in women’s reproductive years, review currently available treatment options, and discuss a personalized treatment approach for women’s reproductive health. Ryan Haumschild, PharmD, MBA, MS, discusses implications of the Affordable Care Act (ACA) to women’s reproductive health, along with methods to ensure timely access to appropriate therapy.

A panel of expert discuss interstitial lung disease (ILD) in depth, from definition to the best possible therapy options for treatment.

A panel of experts explore the patient journey and unmet needs of patients with treatment resistant depression (TRD), outline treatment strategies for TRD outside of oral antidepressants/antipsychotics and explore strategies to support access to these alternative therapies through improved billing/coding strategies.

A panel of clinicians and managed care decision makers describe how to best refer to real-world evidence when making treatment decisions for patients with multiple myeloma.

Payer and clinician insight regarding the integration of comprehensive genomic profiling into routine clinical practice to help oncologists make more informed treatment decisions for patients with cancer.

Expert panelists provide an overview of the burden of MDS, review currently available treatment options, and explore the clinical and payer considerations of oral treatments.

Jim Kenney, RPh, MBA; Kevin U. Stephens, Sr, JD, MD; Philip Niles, MD, MBA; and Nicholas G. Anderson, MD, review the clinical and economic burden of wet AMD and diabetic macular edema (DME), share currently available treatment options, and discuss considerations for emerging ophthalmic therapies.

Neil Minkoff, MD, provides a glimpse at an upcoming Peer Exchange featuring a panel of clinicians and managed care decision makers for a discussion on women’s reproductive health.

This multi-stakeholder roundtable panel discussion will focus on how to address barriers and disparities as obstacles to the use of PrEP, with a focus on increased understanding and education around US Preventive Services Task Force (USPSTF) PrEP guidelines and Affordable Care Act Part 47 for payers and providers.

Expert panelists provide an overview of clinical and managed care considerations in the treatment of glaucoma beyond the first line of therapy.

A panel of experts discuss their personalized approaches to treating patients with psoriasis and comorbidities such as metabolic syndrome.

A panel of experts share payer and clinical considerations for recurrent clostridium difficile infection, including recommend treatment pathways, unmet needs, and emerging therapies.

Clinician and payer insight regarding complexities managing patients with chronic kidney disease and type 2 diabetes, and best practices utilizing newer treatment options.

A discussion on the management of cold agglutinin disease, and the impact of emerging therapies in the pipeline on payer and clinician considerations.

A panel of experts highlight the burden of Alzheimer’s disease and current unmet needs related to diagnosis and treatment, discuss clinical and payer considerations for the diagnosis and management of AD, and generate discussion around future directions in the diagnosis and treatment.

Neil Minkoff, MD; Nihar R. Desai, MD, MPH; Jeffrey Turner, MD; and Om P. Ganda, MD, explore opportunities for improving population health outcomes in cardiorenal metabolic syndrome, including clinical and payer considerations of emerging diabetes treatments.

Neil Minkoff, MD; Ian Frank, MD; Ryan Bitton, PharmD, MBA; Jeffrey Crowley, MPH; and Carl Schmid, MBA explore the current landscape of HIV prevention with PrEP and discuss overcoming barriers to its use.

Dennis P. Scanlon, PhD; Emma Ciafaloni, MD; Maria Lopes, MD, MS; Kevin U. Stephens, Sr, JD, MD; and Mary Schroth, MD, FAAP, FCCP provide an overview of the disease burden in spinal muscular atrophy and give insight into clinical and payor perspectives on screening and diagnosis, current treatment options, and new disease-modifying therapies in SMA.

Bruce Feinberg, DO; Kathy Oubre, Michael Reff, RPh, MBA; Jamile M. Shammo, MD; and Ruben Mesa, MD, discuss the incorporation of quality care programs for improved disease management and patient care for MPNs.

A panel of experts discuss existing treatment options for relapsed/refractory multiple myeloma and provide practical considerations for regimen selection and emerging treatment options.

Key opinion leaders discuss the differences between acute and preventive treatment in migraine, clinical guidelines and treatment selections, and options for migraine management and prevention.

A discussion on the clinical impact of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractor (R/R) non-Hodgkin lymphoma and the role of expanding CAR T administration into the community practice setting.

Optimizing the clinical and financial aspects of disease management when covering an infused drug product under the pharmacy and medical benefit.